Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 437 participants.
Also called NCT02582242
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 437 participants
- Sponsor
- Registry
-
NCT02582242
-
- Other papers using this trial's data
- Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Algeria, China, Hong Kong SAR China, India, Taiwan, Türkiye, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT02582242. Randomized; no masking; primary purpose treatment. Start 2015-10-19 (actual); primary completion 2017-03-18 (actual). Results posted on 2018-05-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin
- Condition
- Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- biphasic insulin aspart 30
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02582242- Content hash
76adbeab8c83bead78fdc47716afef1f5b70743a4e079cdca2a50ee0c3f2dde2